




NB. This includes Healthy Volunteer Trials and sponsor-determined Phase I trials in non-oncology patients. These applications will be assessed and processed within 30 days, with an average of 14 days or less



NB. This includes Phase II-IV trials and sponsor-determined Phase I trials in oncology patients. The initial assessment will be performed within 30 days. For the purposes of this calculation, the day of receipt of the valid application by the Clinical Trials Unit is day 0





NB. The national target for issuing a decision letter for initial VHP national applications is 10 calendar days from date of receipt




NB. The assessment will be performed within 35 days. For the purposes of this calculation, the day of receipt of the valid application by the Clinical Trials Unit is day 0. Amendments for Healthy Volunteer Trials and sponsor-determined Phase I trials in non-oncology patients will be assessed and processed within 35 days, with an average of 14 days or less

Clinical trials for medicines: past years




2007 Applications Received by Phase




NB. Phase II-III and Phase IV data could not be split prior to 2007

2008 Applications Received by Phase




2008 Commercial	232	520	121	873
2008 Non-commercial	12	44	172	228
2008 Total	244	564	293	1101

2009 Applications Received by Phase




2009 Commercial	219	476	77	772
2009 Non-commercial	10	47	207	264
2009 Total	229	523	284	1036

2010 Applications Received by Phase




2010 Commercial	211	457	43	711
2010 Non-commercial	11	57	162	230
2010 Total	222	514	205	941

Clinical Trial Applications Received 2005-2010; Commercial vs Non-commercial




	2005	2006	2007	2008	2009	2010
Commercial	912	829	899	873	772	711
Non-commercial	220	296	309	228	264	230

2011 Applications Received by Phase




	Phase I	Phase 2/3	Phase 4	All Phases
2011 Commercial	216	449	48	713
2011 Non-commercial	16	82	136	234
2011 Total	232	531	184	947

2012 Applications Received by Phase




2012 Commercial	177	518	33	728
2012 Non-commercial	19	81	124	224
2012 Total	196	599	157	952

2013 Applications Received by Phase




2013 Commercial	167	545	47	759
2013 Non-commercial	16	78	139	233
2013 Total	183	623	186	992

2014 Applications Received by Phase




■ 2014 Commercial	163	556	41	760
■ 2014 Non-commercial	11	83	123	217
■ 2014 Total	174	639	164	977

2015 Applications Received by Phase




■ 2015 Commercial	171	622	49	842
■ 2015 Non-commercial	19	79	144	242
■ 2015 Total	190	701	193	1084

2016 Applications Received by Phase




2016 Commercial	134	623	47	804
2016 Non-commercial	9	68	97	174
2016 Total	143	691	144	978

2017 Applications Received by Phase




2017 Commercial	156	635	32	823
2017 Non-commercial	11	86	80	177
2017 Total	167	721	112	1000

2018 Applications Received by Phase




	Phase I	Phase 2/3	Phase 4	All Phases
2018 Commercial	131	630	37	798
2018 Non-commercial	5	78	74	157
2018 Total	136	708	111	955


Clinical Trial Applications Received 2011-2018 Commercial vs Non-commercial



	2011	2012	2013	2014	2015	2016	2017	2018
Commercial	713	728	759	760	842	804	823	798
Non-commercial	234	224	233	217	242	174	177	157



NB. 2005 and 2006 Phase 2/3 includes Phase 4, Phase 2-3 and Phase 4 data could not be split prior to 2007




UK First in Human (FTIH) totals by year




Clinical trials for medicines: previous financial year

All Trials Assessed




	Apr-18	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18	Jan-19	Feb-19	Mar-19
Total Commercial	59	72	55	66	61	62	82	75	65	62	52	67
Total Non Commercial	18	14	10	18	15	13	10	10	13	9	17	10
All	77	86	65	84	76	75	92	85	78	71	69	77


Number of First in Human (FTIH) studies reviewed




Phase I Trials




NB. This includes Healthy Volunteer Trials and sponsor-determined Phase I trials in non-oncology patients. These applications will be assessed and processed within 30 days, with an average of 14 days or less



NB. This includes Phase II-IV trials and sponsor-determined Phase I trials in oncology patients. The initial assessment will be performed within 30 days. For the purposes of this calculation, the day of receipt of the valid application by the Clinical Trials Unit is day 0




NB. The national target for issuing a decision letter for initial VHP national applications is 10 calendar days from date of receipt




NB. The assessment will be performed within 35 days. For the purposes of this calculation, the day of receipt of the valid application by the Clinical Trials Unit is day 0. Amendments for Healthy Volunteer Trials and sponsor-determined Phase I trials in non-oncology patients will be assessed and processed within 35 days, with an average of 14 days or less


Notification Scheme Metrics Apr 2017 - Mar 2018



- Notifications received and considered eligible for the scheme
- Notifications received and considered ineligible for the scheme



NB. **Phase II-IV – Approved after first review** does not include VHP national applications (10 calendar day target) and approved Notification Scheme applications (14 calendar day target)



NB. **Approved after first review** includes VHP national applications and approved Notification Scheme applications

See our [website](#) for recently published material on ‘Common issues identified during clinical trial applications’.